Hyperacidity, GERD, and ulcers:
Indications for: DEXILANT
Healing of all grades of erosive esophagitis (EE). Treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). Maintenance of healing of EE and relief of heartburn.
Adult Dosage:
Swallow whole, or sprinkle granules on 1 tablespoon of applesauce and swallow immediately. EE healing: 60mg cap once daily for up to 8 weeks. Maintenance of healed EE and relief of heartburn: 30mg once daily for up to 6 months in adults or 4 months for ages 12–17. Symptomatic GERD: 30mg once daily for 4 weeks. Moderate hepatic impairment (Child-Pugh Class B) for EE healing: 30mg once day for up to 8 weeks.
Children Dosage:
<12yrs: not established.
DEXILANT Contraindications:
Concomitant rilpivirine-containing products.
DEXILANT Warnings/Precautions:
Symptomatic response does not preclude gastric malignancy. Discontinue and evaluate if acute tubulointerstitial nephritis, cutaneous/systemic lupus erythematosus occurs. Long-term therapy (eg, >3yrs) may lead to malabsorption/deficiency of Vit. B12. Monitor magnesium levels during prolonged therapy. Increased risk for fundic gland polyps with long-term use (esp. >1yr) or risk for osteoporosis-related fractures (hip, wrist or spine) with long-term (>1yr) and multiple daily dose PPI therapy. Use lowest dose for shortest duration appropriate to condition. Risk of heart valve thickening (in children <2yrs old); not recommended. Pregnancy. Nursing mothers.
DEXILANT Classification:
Proton pump inhibitor.
DEXILANT Interactions:
See Contraindications. Avoid concomitant nelfinavir, St. John's Wort, rifampin. May decrease atazanavir levels. May potentiate saquinavir, digoxin, tacrolimus, methotrexate (consider temporary withdrawal of the PPI); monitor. May alter absorption of pH-dependent drugs (eg, iron, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole). Caution with drugs that may cause hypomagnesemia (eg, diuretics); monitor. Monitor warfarin. May cause false (+) results in diagnostic investigations for neuroendocrine tumors; withhold dexlansoprazole ≥14 days prior to CgA level assessment. May cause false (+) urine screening tests for THC; use alternatives. May interfere with secretin stimulation test; withhold dexlansoprazole ≥30 days prior to assessment.
Adverse Reactions:
Diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, flatulence, headache, nasopharyngitis, oropharyngeal pain; possible C. difficile-associated diarrhea; rare: hypomagnesemia.
Generic Drug Availability:
Caps 30mg (NO); 60mg (YES)
How Supplied:
Caps—30, 90, 100, 1000
